CL2024002093A1 - Anticuerpos anti-cd73. - Google Patents
Anticuerpos anti-cd73.Info
- Publication number
- CL2024002093A1 CL2024002093A1 CL2024002093A CL2024002093A CL2024002093A1 CL 2024002093 A1 CL2024002093 A1 CL 2024002093A1 CL 2024002093 A CL2024002093 A CL 2024002093A CL 2024002093 A CL2024002093 A CL 2024002093A CL 2024002093 A1 CL2024002093 A1 CL 2024002093A1
- Authority
- CL
- Chile
- Prior art keywords
- antibodies
- cancer
- diseases
- activity
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
- C12Y301/03005—5'-Nucleotidase (3.1.3.5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962896908P | 2019-09-06 | 2019-09-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2024002093A1 true CL2024002093A1 (es) | 2024-12-27 |
Family
ID=72517218
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2024002093A CL2024002093A1 (es) | 2019-09-06 | 2024-07-10 | Anticuerpos anti-cd73. |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11634500B2 (https=) |
| EP (1) | EP4025605A1 (https=) |
| JP (1) | JP7662617B2 (https=) |
| KR (1) | KR20220057558A (https=) |
| CN (1) | CN115023439B (https=) |
| AU (1) | AU2020342778A1 (https=) |
| BR (1) | BR112022003956A2 (https=) |
| CA (1) | CA3153213A1 (https=) |
| CL (1) | CL2024002093A1 (https=) |
| CO (1) | CO2022002622A2 (https=) |
| IL (1) | IL291068A (https=) |
| MX (1) | MX2022002682A (https=) |
| MY (1) | MY207784A (https=) |
| PE (1) | PE20220708A1 (https=) |
| PH (1) | PH12022550509A1 (https=) |
| TW (1) | TWI859319B (https=) |
| UA (1) | UA130408C2 (https=) |
| WO (1) | WO2021044005A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021138467A1 (en) | 2020-01-03 | 2021-07-08 | Incyte Corporation | Anti-cd73 antibodies and uses thereof |
| CA3166536A1 (en) | 2020-01-03 | 2021-07-08 | Incyte Corporation | Cd73 inhibitor and a2a/a2b adenosine receptor inhibitor combination therapy |
| CN115734972A (zh) * | 2020-06-22 | 2023-03-03 | 信达生物制药(苏州)有限公司 | 抗cd73抗体及其用途 |
| GB202105110D0 (en) * | 2021-04-09 | 2021-05-26 | Cancer Research Tech Ltd | Anti-CD73 antibodies |
| CN119173276A (zh) | 2022-04-13 | 2024-12-20 | 吉利德科学公司 | 用于治疗表达Trop-2的癌症的组合疗法 |
| CN117304316A (zh) * | 2022-06-22 | 2023-12-29 | 复旦大学 | 靶向cd73的纳米抗体及纳米抗体-药物偶联物、其制备方法和用途 |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| CN116178546B (zh) * | 2022-10-13 | 2024-06-18 | 深圳市百士通科技开发有限公司 | 一种多功能重组抗体及其制备方法和应用 |
| US12311033B2 (en) | 2023-05-31 | 2025-05-27 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025076127A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025135233A1 (ko) * | 2023-12-21 | 2025-06-26 | ㈜지아이이노베이션 | Cd73에 특이적으로 결합하는 항체 및 이의 용도 |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025179294A2 (en) | 2024-02-22 | 2025-08-28 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US338841A (en) | 1886-03-30 | herden | ||
| US256055A (en) | 1882-04-04 | Compound engine | ||
| US323997A (en) | 1885-08-11 | Machine-gun | ||
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| AU584417B2 (en) | 1985-04-01 | 1989-05-25 | Lonza Group Ag | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
| US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
| EP1105427A2 (en) | 1998-08-17 | 2001-06-13 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
| MXPA01011279A (es) | 1999-05-07 | 2002-07-02 | Genentech Inc | Tratamiento de enfermedades autoinmunes con antagonistas que se unene a los marcadores de superficie, de celulas b. |
| US6517529B1 (en) | 1999-11-24 | 2003-02-11 | Radius International Limited Partnership | Hemodialysis catheter |
| AU5914201A (en) | 2000-04-25 | 2001-11-07 | Idec Pharma Corp | Intrathecal administration of rituximab for treatment of central nervous system lymphomas |
| WO2004079013A1 (en) | 2003-03-03 | 2004-09-16 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Ecto-5’-nucleotidase (cd73) used in the diagnosis and the treatment of pancreatic cancer |
| EP2062916A3 (en) | 2003-04-09 | 2009-08-19 | Genentech, Inc. | Therapy of autoimmune disease in a patient with an inadequate response to a TNF-Alpha inhibitor |
| WO2006113181A2 (en) | 2005-04-08 | 2006-10-26 | University Of Florida Research Foundation, Inc. | Stem-like cells in bone sarcomas |
| BRPI0612947A2 (pt) | 2005-05-18 | 2010-12-07 | Biogen Idec Inc | método para o tratamento de uma condição fibrótica, método para tratar a fibrose pulmonar, método para tratar a fibrose hepática, método para tratar a fibrose renal, métodos para tratar uma doença fibrótica e método para prevenir uma doença fibrótica |
| WO2007062090A2 (en) | 2005-11-23 | 2007-05-31 | Genentech, Inc. | Methods and compositions related to b cell assays |
| US8975081B2 (en) | 2007-10-24 | 2015-03-10 | Faron Pharmaceuticals Oy | Biomarker for monitoring development of diseases and assessing the efficacy of therapies |
| US20130331297A1 (en) * | 2010-07-16 | 2013-12-12 | Avantgen, Inc. | Novel peptides and uses thereof |
| WO2014153424A1 (en) | 2013-03-19 | 2014-09-25 | La Jolla Institute For Allergy And Immunology | Reducing diabetes in patients receiving hmg-coa reductase inhibitors (statins) |
| US10059761B2 (en) * | 2014-03-12 | 2018-08-28 | Prothena Biosciences Limited | Anti-Laminin4 antibodies specific for LG4-5 |
| IL250579B2 (en) | 2014-10-10 | 2023-05-01 | Innate Pharma | blocking cd73 |
| US20180030144A1 (en) | 2014-10-10 | 2018-02-01 | Innate Pharma | Cd73 blockade |
| DK3218406T4 (da) | 2014-11-10 | 2024-12-09 | Medimmune Ltd | Bindingsmolekyler, der er specifikke for cd73, og anvendelser deraf |
| EP3218407A1 (en) | 2014-11-11 | 2017-09-20 | Medimmune Limited | Therapeutic combinations comprising anti-cd73 antibodies and a2a receptor inhibitor and uses thereof |
| MY189836A (en) * | 2014-11-21 | 2022-03-11 | Bristol Myers Squibb Co | Antibodies against cd73 and uses thereof |
| CA2988119A1 (en) | 2015-06-03 | 2016-12-08 | Dana-Farber Cancer Institute, Inc. | Methods to induce conversion of regulatory t cells into effector t cells for cancer immunotherapy |
| JOP20160154B1 (ar) * | 2015-07-31 | 2021-08-17 | Regeneron Pharma | أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها |
| PL3368572T3 (pl) * | 2015-10-02 | 2022-09-12 | Symphogen A/S | Przeciwciała anty-PD-1 oraz kompozycje |
| US11130817B2 (en) | 2015-10-12 | 2021-09-28 | Innate Pharma | CD73 blocking agents |
| WO2017100670A1 (en) | 2015-12-09 | 2017-06-15 | Corvus Pharmaceuticals, Inc. | Humanized anti-cd73 antibodies |
| WO2017167921A1 (en) | 2016-03-30 | 2017-10-05 | Centre Léon-Bérard | Lymphocytes expressing cd73 in cancerous patient dictates therapy |
| WO2018013611A1 (en) | 2016-07-11 | 2018-01-18 | Corvus Pharmaceuticals, Inc. | Anti-cd73 antibodies |
| MY194596A (en) * | 2016-09-23 | 2022-12-06 | Regeneron Pharma | Bi Specific Anti-Muc16-CD3 Antibodies And Anti-Muc16 Drug Conjugates |
| MY203971A (en) * | 2016-10-13 | 2024-07-26 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Anti-lag-3 antibodies and compositions |
| EP3383916B1 (en) | 2017-01-24 | 2022-02-23 | I-Mab Biopharma US Limited | Anti-cd73 antibodies and uses thereof |
| WO2018187512A1 (en) | 2017-04-04 | 2018-10-11 | Corvus Pharmaceuticals, Inc. | Methods for treating cd73hi tumors |
| WO2018215535A1 (en) | 2017-05-23 | 2018-11-29 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Novel cd73 antibody, preparation and uses thereof |
| CN118307674A (zh) | 2017-06-22 | 2024-07-09 | 诺华股份有限公司 | 针对cd73的抗体分子及其用途 |
| TWI823906B (zh) | 2018-03-09 | 2023-12-01 | 美商艾吉納斯公司 | 抗-cd73 抗體及其使用方法 |
-
2020
- 2020-09-04 US US17/012,942 patent/US11634500B2/en active Active
- 2020-09-04 PH PH1/2022/550509A patent/PH12022550509A1/en unknown
- 2020-09-04 AU AU2020342778A patent/AU2020342778A1/en active Pending
- 2020-09-04 MY MYPI2022001106A patent/MY207784A/en unknown
- 2020-09-04 JP JP2022514681A patent/JP7662617B2/ja active Active
- 2020-09-04 EP EP20772002.0A patent/EP4025605A1/en active Pending
- 2020-09-04 MX MX2022002682A patent/MX2022002682A/es unknown
- 2020-09-04 WO PCT/EP2020/074804 patent/WO2021044005A1/en not_active Ceased
- 2020-09-04 BR BR112022003956A patent/BR112022003956A2/pt unknown
- 2020-09-04 UA UAA202201023A patent/UA130408C2/uk unknown
- 2020-09-04 PE PE2022000364A patent/PE20220708A1/es unknown
- 2020-09-04 KR KR1020227010511A patent/KR20220057558A/ko active Pending
- 2020-09-04 TW TW109130508A patent/TWI859319B/zh active
- 2020-09-04 CN CN202080076881.9A patent/CN115023439B/zh active Active
- 2020-09-04 CA CA3153213A patent/CA3153213A1/en active Pending
-
2022
- 2022-03-02 IL IL291068A patent/IL291068A/en unknown
- 2022-03-04 CO CONC2022/0002622A patent/CO2022002622A2/es unknown
-
2023
- 2023-03-17 US US18/185,848 patent/US20230227573A1/en active Pending
-
2024
- 2024-07-10 CL CL2024002093A patent/CL2024002093A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MY207784A (en) | 2025-03-18 |
| BR112022003956A2 (pt) | 2022-05-24 |
| MX2022002682A (es) | 2022-04-07 |
| CA3153213A1 (en) | 2021-03-11 |
| PH12022550509A1 (en) | 2023-03-20 |
| WO2021044005A1 (en) | 2021-03-11 |
| JP2022547081A (ja) | 2022-11-10 |
| KR20220057558A (ko) | 2022-05-09 |
| JP7662617B2 (ja) | 2025-04-15 |
| PE20220708A1 (es) | 2022-05-04 |
| UA130408C2 (uk) | 2026-02-11 |
| NZ785824A (en) | 2025-10-31 |
| TW202122423A (zh) | 2021-06-16 |
| AU2020342778A1 (en) | 2022-03-31 |
| EP4025605A1 (en) | 2022-07-13 |
| IL291068A (en) | 2022-05-01 |
| US11634500B2 (en) | 2023-04-25 |
| US20230227573A1 (en) | 2023-07-20 |
| CN115023439B (zh) | 2026-04-03 |
| CO2022002622A2 (es) | 2022-04-08 |
| US20210070876A1 (en) | 2021-03-11 |
| TWI859319B (zh) | 2024-10-21 |
| CN115023439A (zh) | 2022-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2024002093A1 (es) | Anticuerpos anti-cd73. | |
| CO2021017845A2 (es) | Proteínas multiespecíficas | |
| CO2018003500A2 (es) | Anticuerpos anti-pd-1 y composiciones | |
| CO2019004003A2 (es) | Composiciones y anticuerpos anti-lag-3 | |
| CL2024001473A1 (es) | Conjugados de fármacos y anticuerpos anti-ccr7 | |
| CO2021001912A2 (es) | Composiciones anti-cd112r y métodos | |
| MX2022003930A (es) | Conjugados de péptido de camptotecina. | |
| MX2022009596A (es) | Anticuerpos anti-ror1 y composiciones. | |
| EA201991214A1 (ru) | Антитела против pd-1 и их композиции | |
| CL2019002461A1 (es) | Arn terapéutico. | |
| MX2018005315A (es) | Composiciones y metodos para el tratamiento del cancer. | |
| ECSP17034845A (es) | Conjugados de anticuerpo- farmaco | |
| BR112019017403A2 (pt) | composições e métodos para o tratamento de câncer | |
| CL2018002698A1 (es) | Tratamiento de enfermedades inflamatorias con inhibidores de actividad c5a | |
| MX2020005567A (es) | Metodos de tratamiento con asparaginasa. | |
| NZ753515A (en) | Methods for treatment of cancer comprising tigit-binding agents | |
| ZA201708265B (en) | Tigit-binding agents and uses thereof | |
| CL2019002427A1 (es) | Inhibición de smarca2 para el tratamiento de cáncer. | |
| GEP20217252B (en) | Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits, and methods | |
| MX2022015250A (es) | Un anticuerpo anti-il-23a para usarse en el tratamiento de la enfermedad de crohn. | |
| ECSP18050575A (es) | Composiciones y métodos para disminuir la expresión de tau | |
| CL2024000459A1 (es) | Tubulisinas y conjugados de proteína-tubulisina. | |
| CL2022002259A1 (es) | Anticuerpos anti-axl y composiciones | |
| MX2019010060A (es) | Composiciones y metodo para tratar cancer. | |
| EA202190504A1 (ru) | Способы лечения псориаза |